16 completed, 5 active not recruiting, 3 terminated, 2 recruiting. 15 Phase 1, 12 Phase 2, 4 Not applicable, 1 Early Phase 1.
Follow pharmacokinetic study: new trials by email Literature Review of pharmacokinetic study trials Research Report on pharmacokinetic study
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs pharmacokinetic study - Bypass Bariatric Surgery | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 64 | 2024-09-01 | 2024-06-14 |
| sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein - Recurrent Bladder Carcinoma, Bladder Cancer Stage 0 | Phase 1 | Withdrawn | University of Southern California | 2023-08-01 | 2023-06-26 | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy Computed Tomography, Copper Cu-64-DOTA-alendronate, Pharmacokinetic Study - Breast Carcinoma, Calcification | Early Phase 1 | Completed | City of Hope Medical Center | 1 | 2021-11-03 | 2024-06-24 |
| Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies genetic study, Pharmacokinetic study, Study of phenotypic activity of cytidine deaminase - Myelodysplastic Syndromes (MDS), Leukemia Acute Myeloid - AML | Not applicable | Recruiting | Assistance Publique Hopitaux De Marseille | 70 | 2021-06-14 | 2025-03-20 |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant Busulfan, Gemcitabine, Melphalan - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 50 | 2019-09-13 | 2026-07-30 |
| Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT Pharmacokinetic study - Citrate Toxicity, Regional Citrate Anticoagulation | Not applicable | Completed | Chulalongkorn University | 20 | 2019-07-01 | 2022-11-14 |
| Itraconazole Pharmacokinetic With and Without Efavirenz Using the Capsule Formulation as Part of Talaromycosis Treatment in HIV-infected Adults Pharmacokinetic study - Pharmacokinetics, Efavirenz | Unknown | Chiang Mai University | 20 | 2019-06-01 | 2019-07-24 | |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Mivavotinib, Paclitaxel, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Ovarian Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 52 | 2019-03-05 | 2023-02-28 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Edicotinib, Pharmacokinetic Study - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2018-10-05 | 2021-12-02 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Terminated | Mayo Clinic | 21 | 2018-08-14 | 2026-05-05 |
| Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery Near-Infrared Fluorescence Imaging, Panitumumab-IRDye800, Pharmacokinetic Study - Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Recruiting | Stanford University | 30 | 2018-07-19 | 2026-10-05 |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study - Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative | Phase 2 | Completed | City of Hope Medical Center | 2 | 2018-06-14 | 2024-02-20 |
| FID-007 in Treating Participants With Advanced Solid Tumors Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 50 | 2018-05-25 | 2026-04-29 |
| BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 19 | 2018-05-23 | 2024-01-08 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
Showing 20 of 29. Sign in to see all of them.
Lymphoma, Non-Hodgkin (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Hodgkin Disease (2) · Lung Neoplasms (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, T-Cell (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Sarcoma (2) · Acute-On-Chronic Liver Failure (1) · Adrenal Cortex Neoplasms (1)
M.D. Anderson Cancer Center (6) · City of Hope Medical Center (4) · National Cancer Institute (NCI) (3) · Stanford University (2) · University of Southern California (2) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · Brenda Cooper, MD (1) · Chiang Mai University (1) · Chulalongkorn University (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1)
United States (23) · France (2) · Puerto Rico (2) · Thailand (2) · South Korea (1)
Alex F Herrera (1) · Alexey Danilov (1) · Amir A Jazaeri (1) · Andrew Cowan (1) · Anthony El-Khoueiry, MD (1) · Asher A. Chanan-Khan, M.D. (1) · Brenda Cooper, MD (1) · Britt K Erickson (1) · Elie Traer, MD (1) · Elizabeth Fox, MD (1) · Ferdinandos Skoulidis, MD,PHD (1) · Floor Backes, MD (1) · Heather Wakelee (1) · Jennifer E Amengual (1)
PMID 22363068, PMID 31401903, PMID 31558469, PMID 36631449, PMID 36658425, PMID 37414012, PMID 38471508, PMID 38608694, PMID 38935895
P30CA014089 (2), P30CA016672 (2), N01CN00033 (1), P30CA014520 (1), P30CA069533 (1), R01CA155196 (1), U10CA180886 (1), UM1CA186689 (1)